Abstract:

Hepatocellular carcinoma （HCC） has become the second leading cause of cancer-related death worldwide， ranking 6th among all tumors. Due to the lack of obvious early symptoms， most patients are diagnosed in the advanced stage， and the clinical benefits of surgical resection and hepatic artery chemoembolization and radiofrequency ablation are very limited. In recent years， the advent of immune-targeted therapies has revolutionized the systemic and systemic treatment of patients with advanced HCC， however， there is a lack of strong clinical evidence on the safety and efficacy of immune and targeted therapies for special populations， including patients with human immunodeficiency virus （HIV） infection， active autoimmune disease， decompensated cirrhosis （Child B or C）， patients with diabetes-associated metabolic syndrome， patients with portal hypertension， vascular invasion， or portal vein thrombosis （PVT）， and patients with liver transplantation （LT）.This article reviews the current research progress of immune and targeted drugs in special populations.

Key words: hepatocellular carcinoma, immuno-targeted therapy, special populations